ApoA1 Trial Misses Endpoint, But HDL Hypothesis Still Alive?
ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.
Medscape Medical News
source https://www.medscape.com/viewarticle/apoa1-trial-misses-endpoint-hdl-hypothesis-still-alive-2024a10006km?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/apoa1-trial-misses-endpoint-hdl-hypothesis-still-alive-2024a10006km?src=rss
Comments
Post a Comment